Case Note & Summary
The case involved appeals by the Union of India against a judgment of the Bombay High Court that quashed the inclusion of seven bulk drugs in the Drugs (Price Control) Order, 1995. The drugs in question were Salbutamol, Theophylline, Cyproflaxacin, Norfloxacin, Cloxacillin, Doxycycline, and Glipizide. The manufacturers of these drugs challenged their inclusion in the price control schedule, arguing that it violated the norms set out in the Drug Policy, 1994, which aimed to ensure transparency and objectivity in price control. The High Court ruled in favor of the manufacturers, stating that the Government had not adhered to its own criteria for inclusion, particularly regarding annual turnover and market competition. The Supreme Court analyzed the criteria for price control, including minimum annual turnover and market share, and found that the Government's methodology for calculating turnover was flawed. The Court emphasized that the term 'turnover' should reflect domestic sales rather than include exports or total production. The Court also noted that the Government had not provided adequate justification for including the drugs under price control despite the absence of monopoly situations. Ultimately, the Supreme Court upheld the High Court's decision, reinforcing the need for the Government to comply with its own established guidelines in exercising delegated legislative powers.
Headnote
A) Administrative Law - Delegated Legislation - Arbitrariness in Inclusion of Drugs - Drugs (Price Control) Order, 1995 - The Government's inclusion of certain drugs in the price control schedule was found arbitrary as it did not adhere to the criteria established in its own Drug Policy, 1994, leading to a violation of Article 14 of the Constitution. The High Court quashed the notices demanding overcharged amounts from manufacturers (Paras 1-2).
Issue of Consideration
Whether the inclusion of certain bulk drugs in the Drugs (Price Control) Order, 1995 was arbitrary and violated the norms set out in the Drug Policy, 1994.
Final Decision
The Supreme Court upheld the High Court's decision, quashing the inclusion of the drugs in the price control schedule and reinforcing the need for adherence to the Drug Policy, 1994 criteria.
Law Points
- Price control
- delegated legislation
- Article 14
- Essential Commodities Act
- Drugs and Cosmetics Act
- Drug Policy
- 1994
- turnover calculation
- market competition
- monopoly situation
